Recombinant Interferon Alfa-2b Research Articles

Treatment of post-COVID-19 patients with chronic recurrent prostatitis: efficacy of recombinant interferon α-2b medications

Introduction. The tactics of managing and treating patients with chronic recurrent bacterial prostatitis (CRBP) in some cases is a difficult-to-treat condition for a practicing urologist. This circumstance occurs because the disease has several predisposing factors, a complex and multifaceted pathogenesis, and certain difficulties in diagnosis and treatment.Objective. To study the effectiveness of recombinant interferon α-2b medications in post-COVID-19 patients with chronic recurrent prostatitis against the background of antibiotic multi-drug resistance of microorganisms verified in prostate secretion.Materials and methods. The treatment of 52 post-COVID-19 patients with CRBP was analyzed, divided into three therapy-dependent groups. Group 1 patients (n = 18) received antibiotic therapy (ABT): Levofloxacin 500 mg q.d. PO for 28 days. Group 2 patients (n = 18) underwent combined therapy: ABT supplemented with recombinant interferon α-2b with an antioxidant complex of vitamins E and C (“Viferon®” rectal suppositories) 3.000.000 IU b.i.d. PR q12h for 28 days. Group 3 patients (n = 16) received monotherapy with recombinant interferon α-2b with an antioxidant complex of vitamins E and C (“Viferon®”rectal suppositories) 3.000.000 IU b.i.d. PR q12h for 28 days. The follow-up period was 6 months with monitoring of clinical and laboratory parameters assessed before treatment, after 1, 3 and 6 months from the start of therapy.Results. Based on the monitoring of the clinical picture and laboratory parameters, after 1 follow-up month, there was a significant decrease in the symptoms of the disease in all study groups. However, after 3 and 6 follow-up months, this trend was observed only in patients of groups 2 and 3 receiving recombinant interferon alfa-2b with an antioxidant complex (vitamins E and C).Conclusions. Strengthening the standard CRBP-therapy with recombinant interferon α-2b with an antioxidant complex of vitamins E and C makes it possible to normalize both clinical and laboratory parameters in most patients.

Prophylactic efficacy of recombinant interferon alfa-2b in pregnant women during their stay in the family with SARS-CoV-2 infection: prospective study

Background. The high contagiousness and susceptibility of a pregnant woman's body to a new coronavirus infection requires study not only of etiopathogenesis, but also of developing methods to prevent the development of this disease.
 Aim. To evaluate the preventive effectiveness of the use of a drug containing recombinant interferon alfa-2b (IFN-a2b) and an antioxidant complex in pregnant women during their stay in the family focus of a new coronavirus infection.
 Materials and methods. 75 pregnant women were under observation, in whose family there were patients infected with the virus that causes a new coronavirus infection. Treatment of sick relatives was carried out at home, as the disease in them proceeded in an uncomplicated form. The main group was formed by 37 pregnant women who treated the nasal mucosa with a preparation containing recombinant IFN-a2b in the amount of 5000 IU and an antioxidant complex (alpha-tocopherol acetate, citric and benzoic acids). The comparison group was formed by 38 pregnant women who did not use any drugs for prophylactic purposes. All patients observed generally accepted rules of personal hygiene and behavior. The duration of prophylactic use of the indicated medicinal product depended on obtaining a negative result for the causative agent of a new coronavirus disease, an infected family member. A smear from the nasopharynx and oropharynx was examined to detect SARS-CoV-2 RNA by PCR once every 57 days.
 Results. COVID-19 vaccination did not exclude infection with the SARS-CoV-2. Preventive treatment of the nasal mucosa with an IFN-a2b containing drug reduced the risk of infection with this viral agent in vaccinated patients who were in household contact with a patient with COVID-19 by 6 times. Asymptomatic and mild course of a new coronavirus infection was observed in 3 (25%) and 7 (58.3%) patients of 12 infected women from the main group and in 8 (22.9%) and 18 (51.4%) patients of 35 infected women from the comparison group, respectively. Further local use of the drug containing recombinant IFN-a2b and an antioxidant complex contributed to a decrease in the duration of infection and the course of the disease. Progression of COVID-19 was observed in unvaccinated patients with concomitant somatic pathology (diabetes mellitus, iron deficiency anemia, cardiovascular diseases, etc.): 2 (16.7%) and 9 (25.7%) people in groups, respectively.
 Conclusion. The use of recombinant IFN-a2b with an antioxidant complex in pregnant women with a family focus of new coronavirus infection is clinically appropriate and highly effective.

Застосування рекомбінантного інтерферону альфа-2b у педіатричній практиці

Система інтерферонів є ключовим елементом противірусного захисту дитячого організму, що етіопатогенетично обґрунтовує застосування назальних та ректальних форм препаратів рекомбінантного інтерферону альфа-2b з метою профілактики та лікування гострих респіраторних вірусних інфекцій у дітей.

The use in pediatrics of recombinant interferon alfa-2b preparations in the dosage form rectal suppositories: whom? when? which ones?

The paper presents the indications and main differences of frequently used rectal suppositories containing interferon alpha-2b.The features and differences in the contained excipients are highlighted. A range of diseases in children's practice is presented, in which candles are shown VIFERON®, Kipferon®, Genferon light®

Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2.

The pandemic distribution of SARS-CoV-2 together with its particular feature of inactivating the interferon-based endogenous response and accordingly, impairing the innate immunity, has become a challenge for the international scientific and medical community. Fortunately, recombinant interferons as therapeutic products have accumulated a long history of beneficial therapeutic results in the treatment of chronic and acute viral diseases and also in the therapy of some types of cancer. One of the first antiviral treatments during the onset of COVID-19 in China was based on the use of recombinant interferon alfa 2b, so many clinicians began to use it, not only as therapy but also as a prophylactic approach, mainly in medical personnel. At the same time, basic research on interferons provided new insights that have contributed to a much better understanding of how treatment with interferons, initially considered as antivirals, actually has a much broader pharmacological scope. In this review, we briefly describe interferons, how they are induced in the event of a viral infection, and how they elicit signaling after contact with their specific receptor on target cells. Additionally, some of the genes stimulated by type I interferons are described, as well as the way interferon-mediated signaling is torpedoed by coronaviruses and in particular by SARS-CoV-2. Angiotensin converting enzyme 2 (ACE2) gene is one of the interferon response genes. Although for many scientists this fact could result in an adverse effect of interferon treatment in COVID-19 patients, ACE2 expression contributes to the balance of the renin-angiotensin system, which is greatly affected by SARS-CoV-2 in its internalization into the cell. This manuscript also includes the relationship between type I interferons and neutrophils, NETosis, and interleukin 17. Finally, under the subtitle of “take-home messages”, we discuss the rationale behind a timely treatment with interferons in the context of COVID-19 is emphasized.

Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration

Ropeginterferon alfa-2b is a novel monopegylated recombinant interferon alfa-2b for the treatment of patients with polycythemia vera. The objectives of this study were to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of ropeginterferon alfa-2b in healthy Japanese subjects compared with Caucasian subjects. In this multicenter, parallel-group phase I study, a cohort consisting of six Japanese and six Caucasian subjects was designated to receive a single subcutaneous dose of ropeginterferon alfa-2b (100, 200, 300, and 450 µg). Pharmacokinetic and pharmacodynamic parameters, and immunogenicity were evaluated. Safety was assessed throughout the study. Cohort 4 (450-µg dose) was not initiated because the primary objective of this study was achieved based on the three completed cohorts. A total of 36 enrolled subjects (18 Japanese and 18 Caucasian) in three cohorts were included in the safety, pharmacokinetic, and pharmacodynamic analysis sets. Ropeginterferon alfa-2b exposure in terms of the area under the serum concentration-time curve (AUC) from time zero extrapolated to infinity and the AUC from time zero to the time of the last quantifiable concentration was approximately 1.7-fold and two-fold higher in Japanese subjects than in Caucasian subjects, respectively. Across the same dose range, the maximum serum concentration was approximately 1.25-fold higher in Japanese subjects than in Caucasian subjects. The time to reach the median maximum serum concentration was similar between ethnicities (approximately 96-111 h). The terminal half-life was 48-57 h in Japanese subjects and 31-75 h in Caucasian subjects. The slope of the relationship between dose and drug exposure was greater than 1 in both ethnicities. The dose-dependent induction of beta-2 microglobulin and neopterin expression was observed in both ethnicities, and the two groups showed similar pharmacodynamic parameters. At the end of the study, 22.2% of Japanese subjects and 11.1% of Caucasian subjects developed anti-ropeginterferon alfa-2b-binding antibodies. The neutralizing capacity of these antibodies was not tested. Ropeginterferon alfa-2b up to 300 µg was safe and well tolerated, with no unexpected safety findings based on previous experiences with ropeginterferon alfa-2b and other forms of interferon. Ropeginterferon alfa-2b exposure was higher in Japanese subjects than in Caucasian subjects. The increase in ropeginterferon alfa-2b exposure was greater than the dose proportion in the dose range of 100-300 µg. Ropeginterferon alfa-2b was safe and well tolerated. ClinicalTrials.gov identifier NCT03546465, registered on 6 June, 2018.

Eficacia y seguridad del interferón pegilado, asociado a la criocirugía en el tratamiento del condiloma acuminado

BackgroundThe continuous recurrences of condylomata acuminata makes it necessary to constantly search for therapeutic alternatives. Patients and methodTo evaluate the therapeutic efficacy and safety of pegylated interferon (IFN p) adjuvant to cryosurgery, an open clinical trial was conducted in condylomata acuminata in 30 patients from the «Hermanos Ameijeiras» hospital, who were randomized to receive 6 weeks (group I) subcutaneous recombinant human interferon alfa 2b (IFN), 3 times per week + biweekly cryosurgery or (group II) subcutaneous IFN p, 1 time per week + biweekly cryosurgery. The main variable was the percentage of recurrence at one year of follow-up. There was also a rigorous control of adverse events. ResultsAt the end of the treatment 12/15 (80%) patients in group I and group II 14/15 (93,3%) were without injuries (p < 0.32). During follow-up, none of the patients who received IFN p + cryosurgery had recurrences; while 2/12 (16.7%) of the patients who received IFN + cryosurgery recurred (p < 0.672). Adverse events were significantly more frequent in group I (fever 13/15, headache 7/15, chills 3/15, and myalgia 2/15) (p < 0.003). ConclusionPegylated interferon with a weekly frequency of administration achieves superior therapeutic effects, a lower percentage of recurrences and adverse reactions than the administration of recombinant human IFN alpha 2b 3 times a week.

COVID-19 in pregnancy: special characteristics of the course and rational therapy with recombinant interferon alfa-2b formulations

<h3>ЦЕЛЬ ИССЛЕДОВАНИЯ</h3> Оценка эффективности и безопасности сочетанного применения препаратов интерферона альфа-2b в комплексе с антиоксидантами Виферон в форме суппозиториев ректальных 3 000 000 МЕ и геля для наружного и местного применения 36 000 МЕ/г в лечении беременных, больных новой коронавирусной инфекцией (НКИ) COVID-19. <h3>МАТЕРИАЛ И МЕТОДЫ</h3> В исследование были включены 140 беременных с подтвержденным диагнозом НКИ COVID-19. Беременные были распределены в две группы по 70 человек в каждой: 1-я группа получала препараты Виферон и стандартную комплексную терапию; 2-я группа — только стандартную терапию. Оценку эффективности терапии проводили путем сравнительного анализа динамики симптомов заболевания, лабораторных показателей и исходов родов. <h3>РЕЗУЛЬТАТЫ</h3> Включение в схему стандартной комплексной терапии беременных с НКИ COVID-19 препаратов интерферона альфа-2b с антиоксидантным комплексом позволило добиться более быстрого купирования основных симптомов заболевания и развития стойкого противовирусного иммунного ответа. Значимое снижение уровня провоспалительного цитокина ИЛ-6 на фоне комплексной терапии препаратами Виферон (интерферон альфа-2b с антиоксидантами) является благоприятным прогностическим критерием восстановления после перенесенного заболевания. На основании анализа исходов родов в зависимости от проводимой терапии получены данные, подтверждающие эффективность и безопасность комплексной терапии с включением препаратов Виферон у беременных 1-й группы. Большая часть родов произошла в срок 38—40 нед, не зафиксировано перинатальных потерь. У беременных 2-й группы, получавших только стандартную терапию, зафиксирована антенатальная гибель плода в двух наблюдениях. <h3>ЗАКЛЮЧЕНИЕ</h3> Включение препаратов интерферона альфа-2b c антиоксидантами Виферон в форме ректальных суппозиториев и геля для наружного и местного применения в комплексную терапию беременных с COVID-19 способствует более быстрому купированию симптомов заболевания, развитию стойкого иммунного ответа и рождению новорожденных в удовлетворительном состоянии.

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera

ABSTRACT Introduction Polycythemia vera (PV) is a Philadelphia chromosome-negative chronic myeloproliferative neoplasm (MPN). A newly developed PV treatment option, ropeginterferon alfa-2b, contains recombinant human alfa monoisomer as an active ingredient, resulting in a novel pharmacologic profile and improved tolerability. Efficacy studies conclude remarkable long-term hematological response and sustained JAK2V617F allele burden reduction. Ropeginterferon alfa-2b compound has been approved for the treatment of polycythemia vera without symptomatic splenomegaly. Areas covered Current clinical trials are investigating the role of ropeginterferon alfa-2b in the first-line setting of treatment for PV. The safety and efficacy results of completed trials are summarized in this review. Metabolic, pharmacokinetic issues are also discussed of ropeginterferon alfa-2b. Expert opinion Ropeginterferon alfa-2b is a targeted therapeutic option in the treatment of PV, representing a significant improvement compared to conventional cytoreductive therapies. The single isomer entity of the recombinant human interferon alfa-2b and the mono-pegylation method imparts favorable properties to the compound. The use of ropeginterferon alfa-2b allows extended dosing interval, reduces side effects, and may increase the overall survival of PV patients by reducing the risk of progression to myelofibrosis or acute leukemia. Clinical data suggests that the compound may provide a disease-modifying option for PV patients with asymptomatic splenomegaly.

Safety and efficacy of intranasal recombinant human interferon alfa 2b as prophylaxis for COVID-19 in patients on a hemodialysis program

Introduction: Patients diagnosed with end-stage chronic kidney disease on a hemodialysis program (HDP) represent a risk group for COVID-19. Scientific societies have developed guidelines for the prevention of contagion, but there is no prophylactic medicine in them. Objectives: To describe the safety and efficacy of recombinant intranasal human Interferon alfa 2b as prophylaxis for COVID-19 in patients in an HDP. Patients and Methods: Intervention description through the monitoring of 15 patients in outpatient HDP. Prior to the administration of the drug, clinical, radiological evaluation and hematology and blood chemistry studies were performed. Daily contact was made with each study patient in person or by telephone, asking about the occurrence of adverse events or symptoms of disease. Results: In 47% of the patients, there was leukopenia, lymphopenia in 67% and anemia and thrombocytopenia in 33% respectively, prior to the use of the drug. There was no clinical suspicion of COVID-19 in any of them. Adverse events occurred in 3 patients (20%), all were mild and non-severe. All patients were negative for SARS-CoV-2 real-time polymerase chain reaction (rtPCR) and antibody studies 45 days after the study started. Conclusion: the use of intranasal recombinant human interferon alfa 2b as prophylaxis of COVID-19 in patients in a HDP at a dose of 1 MIU daily for ten days, as part of a prevention protocol, has an adequate safety profile. None of the patients in the series was infected with SARS-CoV-2 during the surveillance period.

A COVID-19 patient with multiple negative results for PCR assays outside Wuhan, China: a case report

BackgroundThe outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a public health emergency of major international concern. Real-time RT-PCR assays are recommended for diagnosis of COVID-19. Here we report a rare case of COVID-19 with multiple negative results for PCR assays outside Wuhan, China.Case presentationA 32-year old male was admitted to our hospital because of 6 days of unexplained fever on January 29, 2020. He had come from Wuhan city 10 days before admission. Five days before admission, no abnormality was noted in laboratory test, chest radiography, and nasopharyngeal swab test for the SARS-CoV-2 nucleic acid. The patient was treated with ibuprofen for alleviating fever. On admission, chest computed tomography showed multiple ground-glass opacities in right lower lung field. COVID-19 was suspected. Three times of nasopharyngeal swab specimens were collected after admission. However, none of the specimens were positive. The patient was confirmed with COVID-19 after fifth SARS-CoV-2 nucleic acid test. He was treated with lopinavir/ritonavir, recombinant human interferon alfa-2b inhalation, methylprednisolone. After 18 days of treatment, he was discharged with improved symptoms, lung lesions and negative results of nasopharyngeal swab.ConclusionThis case reminds clinician that a patient with high clinical suspicion of COVID-19 but multiple negative RT-PCR result should not be taken out of isolation. A combination of patient’s exposure history, clinical manifestations, laboratory tests, and typical imaging findings plays a vital role in making preliminary diagnosis and guide early isolation and treatment. Repeat swab tests are helpful in diagnosis for this kind of patients.

Еxternal forms of recombinant interferon alfa-2b - ointment and gel in the treatment of acute respiratory viral infections and influenza in children

The review article presents the results of numerous studies on the effectiveness and safety of the newly developed forms of the human recombinant interferon alpha- 2b drug, ointment and gel, intended for the treatment and prevention of acute respiratory viral infections and influenza in children. Еxternal forms of the drug retain immunomodulatory, antiviral and antiproliferative effects. The dosage form of the preparation of interferon alpha-2b VIFERON® in the form of a gel or ointment allows to achieve a prolonged action due to good absorption, especially the gel, which increases its effectiveness, and also has a moisturizing effect and rarely causes allergies. All of the above properties justify the inclusion of the drug interferon alpha-2b VIFERON® in the form of a gel or ointment in the complex treatment of influenza and acute respiratory viral infections in children.

Сравнительная оценка воспалительных фенотипов бронхиальной астмы у детей при проведении профилактического курса препарата рекомбинантного интерферона альфа-2b

Сравнительная оценка воспалительных фенотипов бронхиальной астмы у детей при проведении профилактического курса препарата рекомбинантного интерферона альфа-2b

The effectiveness of the use of the drug recombinant interferon alfa-2b for the prevention of acute respiratory infections in preschool children

Acute respiratory infections (ARI) are the most common diseases of children, the main reasons for which are the age-related characteristics of the immune response, exacerbated by adverse perinatal factors, allergies, and increased contact with potential pathogens (the beginning of visits to preschool institutions, etc.).Objective: to evaluate the effectiveness of the use of the drug recombinant interferon α-2b to reduce the incidence of acute respiratory infections in preschool children.Throughout the year, there were 50 children under observation (average age 29.2 ± 0.97 months) attending preschool institutions. Recombinant interferon α-2b, ointment — VIFERON® 2500 IU 2 times a day for 14 days, in the next 4 weeks — 2500 IU 2 times a day 3 times a week was used for 25 children of the main group for the prevention of ARI in the pre-epidemic period.Results: The use of recombinant interferon α-2b in children of the main group showed a statistically significant decrease in the incidence of ARI, pneumonia, otitis, and the disappearance of pathological symptoms in the nasopharynx. An increase in the level of antiviral cytokines (IFN-α, p = 0.0088, IFN-γ, p = 0.0014) and a decrease in the concentration of pro-inflammatory (IL-1β, p = 0.0072) were recorded. Carriage of S. aureus, S. epidermidis, Candida albicans decreased by 2 times. Decrease in titer of antibodies to Str. pyogenes (p = 0.0251), Str. pneumoniae (p = 0.0491), Branchamella catarrhalis (p = 0.0369), Haemophilus influenzae (p = 0.0251) indicates a decrease in the sensitization of the child's organism to microbial antigens.

Тhe prophylactic efficacy of a recombinant interferon alfa-2b drug in children with bronchial asthma

A prospective cohort study was conducted to assess the effect of a recombinant interferon alpha-2b prophylactic course on cyto-immunological parameters of induced sputum in children with mild asthma, the main trigger of exacerbation of which was respiratory viral infections.We examined 40 children aged 1 to 7 years with (mean age — 4.8 ± 0.2 years), half of whom received a course of recombinant interferon alpha-2b. The authors detected respiratory viruses in scrapings from throat and nose (PCR method) and evaluated the different cell counts, also the levels of interleukin-10, tumor necrosis factor alpha, interferon alpha and immunoglobulin E on the 1st and 30th day of the study (ELISA method) were determined in sputum.The number of asthma exacerbations, triggered by respiratory viral infection, decreased in 4.5 times against. In children who received recombinant interferon alpha-2b the count of sputum eosinophils and the number of children with sputum eosinophilia (≥3 %) reduced. After two months the level of nasal eosinophils was 30% lower than the start level. The level of IgE in induced sputum decreased by 35%, but the level of IL-10 was increased by 1.5 times. 75% of parents whose children received recombinant interferon alpha-2b, note positive effect of this drug.There were no adverse events to receive the drug in any case. Thus, the use of recombinant interferon alpha-2b in children with virus-induced asthma to reduce episodes of exacerbations associated with acute respiratory diseases can be recommended.

Vaginal biocenosis in pregnant women with recurrent bacterial vaginosis after treatment with recombinant human interferon alpha-2b

Introduction.Preventing recurrent bacterial vaginosis (BV) during pregnancy is an important issue in current obstetrics.Aim:to assess the effect of recombinant human interferon alpha-2b on the incidence of recurrent BV during pregnancy and on the bacterial, cytokine, and antimicrobial components of the nonspecific vaginal immunity.Materials and methods.The study included 80 pregnant women with recurrent BV, 40 of whom (the main group) were treated with recombinant human interferon alpha-2b in the first half of pregnancy and after 30 weeks of pregnancy in addition to standard therapy (metronidazole or clindamycin). The other 40 women (control group) did not receive this interferon drug. Patients of the both groups were examined for the rate of BV recurrence and also tested for their vaginal bacteria and levels of β-defensin-2 (HBD-2), interleukin-1β (IL-1β), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), and interferon-γ (INF-γ) in the third trimester of pregnancy.Results.Treatment with recombinant human interferon alfa-2b led to a 3-fold reduction in the occurrence of repeated episodes of BV and an increase in the content of lactobacilli (7.24 ± 0.33 and 7.03 ± 0.40 in patients with interferon therapy and without it, respectively; p = 0.013) mainly due to Lactobacillus crispatus (7.14 ± 0.69 in women who received interferon alfa-2b, compared with 6.36 ± 0.95 in patients on standard therapy; p = 0.003) and a decrease in the number of some types of anaerobes. Also, the use of interferon alpha-2b in pregnant women with recurrent BV led to an increase in the content of IL-1β by 2.5 times, IL-6 by 3.5 times, IL-10 by 1.5 times, INF-γ by 2 times, and HBD-2 by 4 times.Conclusion.Treatment of recurrent BV during pregnancy with recombinant human interferon alfa-2b, aimed at boosting the nonspecific vaginal immunity helps reduce the incidence of recurrent BV.

EFFICIENCY, SAFETY AND POSSIBILITIES OF IMMUNOTROPIC THERAPY AFTER SURGICAL TREATMENT OF ENDOMETRIOSIS

The identification of the immune system disorders along with the impact on the causative agent and correction of such disorders is of great importance in the therapy of patients with endometritis. It has been established that the infectious agents are eliminated by the phagocytic system cells, therefore the optimal choice for the activation of anti-infective immunity are the immunomodulators acting on the monocyte-macrophage system cells. Use of immunomodulators: recombinant human interleukin-2 (Roncoleukin®, IL-2) and Interferon alfa-2b + Taurine + Benzocaine (Genferon®) in combination with the standard therapy showed its safety and efficiency in treating patients with endometritis after caesarean section.

THE IMPACT OF THE METHOD OF PREVENTION OF INTRAUTERINE INFECTION ON THE STATE OF NONSPECIFIC IMMUNITY IN PREGNANT WOMEN WITH RELAPSING HERPETIC INFECTION AND THEIR CHILDREN

Purpose of the study: to assess the state of nonspecific immunity in women with relapsing herpetic infection, planning pregnancy, period of gestation, from infants and children in the first six months of life, depending on the method of prophylaxis of relapses of infection and intrauterine infection. Patients and methods: under observation were 342 pregnant women with relapsing herpetic infection and their children. Testing for the presence of HSV infection was performed using methods of PCR and ELISA. Women and their children were studied: interferon status, indicators of phenotyping of lymphocytes, the levels of tumor necrosis factor, growth factor of the placenta, placental alkaline phosphatase, placental alpha-1 microglobulin, interleukin 10, immunoglobulin classes A, M, G; for the assessment of fetoplacental complex was used ultrasonic methods. The health status of infants and children in the first six months of life was estimated taking into account the diagnosis of intrauterine infection with herpes simplex virus and realization of somatic pathology. Results of the study: validated method of prevention of intrauterine infection of the fetus with the use of the drug Alloferon on degustatsionnom stage and human recombinant interferon Alfa-2b in the antenatal period. A proven Association between the efficiency of consequent preventive therapy and frequency of complications of gestation, intrauterine infection with herpes simplex virus, the state of nonspecific immunity in pregnant women, newborns and children in the first six months of life. Conclusion: for recurrent herpes infection during pregnancy, an imbalance in the system of nonspecific immunity, development planetarnoi failure lead to tensions antiinfectious immunity in the neonatal period in children with intrauterine infection, and in uninfected children. Newborn children with the implementation of the herpes infection observed inhibition of nonspecific immunity. Milestone method of prevention of intrauterine infection of the fetus with the use of drugs Alloferon and human recombinant interferon Alfa-2b meets the modern requirements of perinatal pharmacology, accessible and safe.

Enhancement of interferon treatment for large basaliomas

Background: Treatment of large basaliomas may be problematic, because relapses after the use of various treatment modalities are frequent. Aim : To assess the efficacy of interferon therapy for primary solitary T2N0M0 basalioma. Materials and methods : We retrospectively analyzed the results of treatment of 72 patients with primary solitary basalioma T2N0M0. The patients from the main group (n = 35) were treated with injections of recombinant interferon alfa 2b into the lesion at a dose of 2 to 3 Mio IU (total dose for the treatment course from 18 to 27 Mio IU). The reference group included 37 patients treated by cryodestruction. The results were assessed at 8 weeks after the end of interferon therapy and at 3 months after cryotherapy. The cure was confirmed cytologically at 3 months after clinical reconvalescence (formation of the scarring atrophy area or re-epithelization). Results : The treatment was effective in 100% (35/35) of the patients from the main group. Twenty nine (82.9%) cases of basalioma required two courses of interferon therapy, 5 (14.3%) cases 3 courses, and one case (2.8%) 4 courses. In the reference group, 94.6% (35/37) of patients were cured. The difference between the proportions of the cured patients between the two groups was 5.4% (confidence interval (CI) -5.2–17.7%). Within the next 3 years of the follow-up there were no relapses in the main group, whereas the relapses were diagnosed in 9 (24.3%) of the patients from the reference group. The difference of the proportions between the two groups was 24.3% (CI 9.6–40%). Conclusion : Based on the short- and long-term results, the efficacy of intralesional interferon administration in basalioma T2N0M0 was 100%. For tumors of more than 2 cm², an increase of the single and the total cumulative dose of recombinant interferon alfa 2b is necessary, as well as several courses of interferon treatment. Interferon therapy is more effective than cryodestruction based on the 3-year relapse-free survival.

THE DYNAMICS OF THE IMMUNE RESPONSEМ TO INFLUENZA IN CHILDREN TREATED WITH INTERFERON

The paper presents clinical and laboratory study results of the immune response indicators dynamics in 199 children aged 1 year to 14 years with verified diagnosis of influenza depending on the type of immune response to the treatment with recombinant interferon alpha-2b (IFN) (Grippferon®, nasal drops). A total of 100 people received this medication, whereas 99 patients in the control group received pathogenetic therapy. The immune response type was determined on the basis of the polarisation coefficients (PC) suggested by the authors: PC1 = IL-4/IFN- γ and PC2 = IL-10/IFN- γ obtained by calculating the content ratio in the serum cytokines of IL-4 to IFN- γ and IL-10 to IFN- γ , responsible for the predominant type of immune response to antigen introduction. A good therapeutic efficacy of the intranasal medication of recombinant interferon alfa-2b was established for the treatment of influenza in children, given both the Th1and Th2-type immune response. This allows us to recommend this medication for use in children, regardless of the immune response type.